📊 ALT Key Takeaways
Is Altimmune, Inc. (ALT) a Good Investment?
Altimmune is a pre-commercial pharmaceutical company with devastating operational losses (-$24.2M operating income on only $41K revenue) and a cash burn rate of $20.9M annually. While the balance sheet is strong with $97.6M cash and low debt (0.12x D/E), the company demonstrates no viable path to profitability based on fundamental metrics, making it unsuitable for investors seeking financial health outside of pure R&D stage biotech speculation.
Altimmune’s fundamentals reflect a clinical-stage biotech with negligible revenue, deeply negative margins, and substantial operating and free cash flow burn, so the business is not yet financially self-sustaining. The balance sheet is currently a relative strength, with high liquidity, modest leverage, and meaningful equity, but the present cash position appears light versus the annual burn rate. Growth quality is weak because the reported revenue increase is from a very small base and does not offset persistent losses.
Altimmune, Inc. Key Strengths (ALT)
- Strong balance sheet with $284M stockholders equity and minimal debt (0.12x D/E ratio)
- Substantial cash position ($97.6M) providing ~4.7 year runway at current burn rate
- Exceptional liquidity (29.56x current ratio) ensures near-term financial stability
- Strong near-term liquidity with current and quick ratios of 18.55x
- Low leverage with debt/equity of 0.15x and substantial equity of $224.89M
- Asset base remains solid relative to liabilities, supporting financial flexibility
ALT Stock Risks: Altimmune, Inc. Investment Risks
- Catastrophic profitability with -$24.2M operating losses on negligible $41K revenue base
- Unsustainable cash burn of $20.9M annually with negative operating cash flow
- No demonstrated commercialization capability; remains pre-clinical/early-stage with zero revenue-generating business
- Extremely negative operating margin (-59,131.7%) indicating business model is not yet viable
- Extremely weak profitability with operating loss of $94.49M and net loss of $88.09M
- Cash burn is high, with operating cash flow of -$67.53M and free cash flow of -$67.55M
- Revenue base is immaterial at $41K, making growth quality poor and increasing dependence on external funding
Key Metrics to Watch
- Quarterly revenue growth and path to commercial product launch
- Monthly cash burn rate trend and runway longevity
- Operating loss trajectory and achievement of clinical milestones
- Cash runway versus operating cash burn
- Progression of R&D-driven losses relative to any meaningful revenue generation
Altimmune, Inc. (ALT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 29.56x current ratio provides a solid financial cushion.
ALT Profit Margin, ROE & Profitability Analysis
ALT vs Healthcare Sector: How Altimmune, Inc. Compares
How Altimmune, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Altimmune, Inc. Stock Overvalued? ALT Valuation Analysis 2026
Based on fundamental analysis, Altimmune, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Altimmune, Inc. Balance Sheet: ALT Debt, Cash & Liquidity
ALT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Altimmune, Inc.'s revenue has declined by 24% over the 5-year period, indicating business contraction. The most recent EPS of $-1.34 indicates the company is currently unprofitable.
ALT Revenue Growth, EPS Growth & YoY Performance
ALT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $5.0K | -$19.6M | $-0.18 |
| Q3 2025 | $5.0K | -$19.0M | $-0.21 |
| Q2 2025 | $5.0K | -$19.6M | $-0.27 |
| Q1 2025 | $5.0K | -$19.6M | $-0.26 |
| Q3 2024 | $5.0K | -$16.1M | $-0.32 |
| Q2 2024 | $5.0K | -$16.1M | $-0.32 |
| Q1 2024 | $5.0K | -$20.1M | $-0.34 |
| Q3 2023 | $2.0K | -$16.1M | $-0.39 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Altimmune, Inc. Dividends, Buybacks & Capital Allocation
ALT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Altimmune, Inc. (CIK: 0001326190)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ALT
What is the AI rating for ALT?
Altimmune, Inc. (ALT) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ALT's key strengths?
Claude: Strong balance sheet with $284M stockholders equity and minimal debt (0.12x D/E ratio). Substantial cash position ($97.6M) providing ~4.7 year runway at current burn rate. ChatGPT: Strong near-term liquidity with current and quick ratios of 18.55x. Low leverage with debt/equity of 0.15x and substantial equity of $224.89M.
What are the risks of investing in ALT?
Claude: Catastrophic profitability with -$24.2M operating losses on negligible $41K revenue base. Unsustainable cash burn of $20.9M annually with negative operating cash flow. ChatGPT: Extremely weak profitability with operating loss of $94.49M and net loss of $88.09M. Cash burn is high, with operating cash flow of -$67.53M and free cash flow of -$67.55M.
What is ALT's revenue and growth?
Altimmune, Inc. reported revenue of $41.0K.
Does ALT pay dividends?
Altimmune, Inc. pays dividends, with $200.3M distributed to shareholders in the trailing twelve months.
Where can I find ALT SEC filings?
Official SEC filings for Altimmune, Inc. (CIK: 0001326190) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ALT's EPS?
Altimmune, Inc. has a diluted EPS of $-0.18.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ALT's fundamental grade?
Based on our AI fundamental analysis in June 2026, Altimmune, Inc. has a C grade with 82% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ALT stock overvalued or undervalued?
Valuation metrics for ALT: ROE of -7.9% (sector avg: 15%), net margin of -55,031.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ALT's AI grade for 2026?
Our dual AI analysis gives Altimmune, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ALT's free cash flow?
Altimmune, Inc.'s operating cash flow is $-20.9M, with capital expenditures of $21.0K. FCF margin is -51,129.3%.
How does ALT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -55,031.7% (avg: 12%), ROE -7.9% (avg: 15%), current ratio 29.56 (avg: 2).